CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP)
US23254L2079
We assign a fundamental rating of 3 out of 10 to CYCCP. CYCCP was compared to 587 industry peers in the Biotechnology industry. The financial health of CYCCP is average, but there are quite some concerns on its profitability. CYCCP is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CYCCP has reported negative net income.
In the past year CYCCP has reported a negative cash flow from operations.
In the past 5 years CYCCP always reported negative net income.
In the past 5 years CYCCP always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of CYCCP (-258.41%) is worse than 92.48% of its industry peers.
The Return On Equity of CYCCP (-3748.43%) is worse than 84.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -258.41% | ||
| ROE | -3748.43% | ||
| ROIC | N/A |
ROA(3y)-127.03%
ROA(5y)-93.46%
ROE(3y)-1302.39%
ROE(5y)-802.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CYCCP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CYCCP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CYCCP has been reduced compared to 1 year ago.
Compared to 5 years ago, CYCCP has more shares outstanding
There is no outstanding debt for CYCCP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -77.08, we must say that CYCCP is in the distress zone and has some risk of bankruptcy.
CYCCP has a worse Altman-Z score (-77.08) than 96.07% of its industry peers.
CYCCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -77.08 |
ROIC/WACCN/A
WACC9.14%
2.3 Liquidity
A Current Ratio of 0.91 indicates that CYCCP may have some problems paying its short term obligations.
CYCCP's Current ratio of 0.91 is on the low side compared to the rest of the industry. CYCCP is outperformed by 89.91% of its industry peers.
A Quick Ratio of 0.91 indicates that CYCCP may have some problems paying its short term obligations.
CYCCP has a Quick ratio of 0.91. This is amonst the worse of the industry: CYCCP underperforms 89.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.91 | ||
| Quick Ratio | 0.91 |
3. Growth
3.1 Past
CYCCP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -164.37%.
The Revenue has been growing by 22.87% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-164.37%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q30.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y22.87%
Revenue growth Q2QN/A
3.2 Future
CYCCP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.74% yearly.
CYCCP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 233.35% yearly.
EPS Next Y49.88%
EPS Next 2Y4.27%
EPS Next 3Y27.29%
EPS Next 5Y19.74%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y631.97%
Revenue Next 5Y233.35%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CYCCP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CYCCP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CYCCP's earnings are expected to grow with 27.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.27%
EPS Next 3Y27.29%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 7.14%, CYCCP is a good candidate for dividend investing.
In the last 3 months the price of CYCCP has falen by -69.19%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
CYCCP's Dividend Yield is rather good when compared to the industry average which is at 25.72. CYCCP pays more dividend than 98.97% of the companies in the same industry.
CYCCP's Dividend Yield is rather good when compared to the S&P500 average which is at 2.34.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 7.14% |
5.2 History
The dividend of CYCCP decreases each year by -38.18%.
CYCCP has been paying a dividend for over 5 years, so it has already some track record.
The dividend of CYCCP decreased in the last 3 years.
Dividend Growth(5Y)-38.18%
Div Incr Years0
Div Non Decr Years2
5.3 Sustainability
CYCCP has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-0.88%
EPS Next 2Y4.27%
EPS Next 3Y27.29%
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP
NASDAQ:CYCCP (5/8/2024, 7:00:00 PM)
6.3
-0.06 (-0.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.32M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 7.14% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -258.41% | ||
| ROE | -3748.43% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.91 | ||
| Quick Ratio | 0.91 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-164.37%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y49.88%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y